Salud financiera de hoja de balance de MDxHealth

Salud financiera controles de criterios 4/6

MDxHealth tiene un patrimonio de los accionistas total de $17.8M y una deuda total de $36.0M, lo que sitúa su ratio deuda-patrimonio en 201.8%. Sus activos y pasivos totales son $135.7M y $117.9M respectivamente.

Información clave

201.8%

Ratio deuda-patrimonio

US$36.01m

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$32.71m
Patrimonio	US$17.84m
Total pasivo	US$117.89m
Activos totales	US$135.73m

Actualizaciones recientes sobre salud financiera

Recent updates

Why Investors Shouldn't Be Surprised By MDxHealth SA's (EBR:MDXH) 29% Share Price Plunge

Oct 05

MDxHealth (EBR:MDXH) Has Debt But No Earnings; Should You Worry?

Aug 29

MDxHealth (EBR:MDXH) Is Carrying A Fair Bit Of Debt

Apr 21

Is MDxHealth (EBR:MDXH) Using Debt In A Risky Way?

May 05

Here's Why MDxHealth (EBR:MDXH) Can Manage Its Debt Despite Losing Money

Nov 08

MDxHealth (EBR:MDXH) Has Debt But No Earnings; Should You Worry?

Mar 23

MDxHealth's (EBR:MDXH) Stock Price Has Reduced 75% In The Past Five Years

Jan 29

Is MDxHealth (EBR:MDXH) Weighed On By Its Debt Load?

Nov 27

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($45.6M) de MDXH superan a sus pasivos a corto plazo ($18.8M).

Pasivo a largo plazo: Los activos a corto plazo ($45.6M) de MDXH no cubren sus pasivos a largo plazo ($99.0M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: El ratio deuda neta-patrimonio (18.5%) de MDXH se considera satisfactorio.

Reducción de la deuda: El ratio deuda-patrimonio de MDXH ha crecido de 0.3% a 201.8% en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: MDXH tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.

Pronóstico de cash runway: MDXH dispone de suficiente cash runway para más de 3 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 6.9% cada año

Salud financiera de hoja de balance de MDxHealth

Salud financiera controles de criterios 4/6

Información clave

Actualizaciones recientes sobre salud financiera

MDxHealth SA Shares No Longer Be Listed and Traded on Euronext Brussels, Effective as of Close of Trading on Euronext Brussels on December 15, 2023

MDxHealth SA Shares No Longer Be Listed and Traded on Euronext Brussels, Effective as of Close of Trading on Euronext Brussels on December 15, 2023

MDxHealth (EBR:MDXH) Has Debt But No Earnings; Should You Worry?

MDxHealth (EBR:MDXH) Is Carrying A Fair Bit Of Debt

Is MDxHealth (EBR:MDXH) Using Debt In A Risky Way?

Here's Why MDxHealth (EBR:MDXH) Can Manage Its Debt Despite Losing Money

Recent updates

MDxHealth SA Provides Revenue Guidance for the Year 2025

MDxHealth SA has filed a Follow-on Equity Offering in the amount of $40 million.

Mdxhealth SA Raises Earnings Guidance for the Year 2024

MDxHealth SA Revises Earnings Guidance for the Year 2024

MDxHealth SA has filed a Follow-on Equity Offering in the amount of $50 million.

Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offering

MDxHealth SA Maintains Earnings Guidance for the Year 2024

MDxHealth SA Announces Jan Pensaert Steps Down from its Board of Directors

MDxHealth SA Provides Earnings Guidance for the Fourth Quarter and Full Year 2023 and Year 2024

MDxHealth SA to Report Q1, 2024 Results on May 08, 2024

MDxHealth SA Shares No Longer Be Listed and Traded on Euronext Brussels, Effective as of Close of Trading on Euronext Brussels on December 15, 2023

MDxHealth SA Shares No Longer Be Listed and Traded on Euronext Brussels, Effective as of Close of Trading on Euronext Brussels on December 15, 2023

New minor risk - Profitability

MDxHealth SA Provides Earnings Guidance for the Year 2023

MDxHealth SA Revises Earnings Guidance for the Year 2023

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Why Investors Shouldn't Be Surprised By MDxHealth SA's (EBR:MDXH) 29% Share Price Plunge

MDxHealth SA to Report Q3, 2023 Results on Oct 09, 2023

Consensus EPS estimates fall by 10%, revenue upgraded

MDxHealth (EBR:MDXH) Has Debt But No Earnings; Should You Worry?

New major risk - Share price stability

MDxHealth SA Reaffirms Revenue Guidance for the Year 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

MDxHealth (EBR:MDXH) Is Carrying A Fair Bit Of Debt

Full year 2022 earnings released: US$0.28 loss per share (vs US$0.24 loss in FY 2021)

Third quarter 2022 earnings released: US$0.078 loss per share (vs US$0.06 loss in 3Q 2021)

MDxHealth SA to Report First Half, 2023 Results on Aug 23, 2023

MDxHealth SA Provides Revenue Guidance for the Fiscal Year 2023

MDxHealth SA Revises Revenue Guidance for the Fiscal Year 2022

Price target increased to €1.20

MDxHealth SA Reaffirms Revenue Guidance for the Year 2022

Third quarter 2022 earnings released: US$0.05 loss per share (vs US$0.059 loss in 3Q 2021)

Second quarter 2022 earnings released: US$0.072 loss per share (vs US$0.06 loss in 2Q 2021)

MDxHealth SA (ENXTBR:MDXH) acquired Oncotype DX GPS Prostate Cancer Business from Exact Sciences Corporation (NasdaqCM:EXAS) for $100 million.

MDxHealth SA (ENXTBR:MDXH) acquired Oncotype DX GPS Prostate Cancer Business from Exact Sciences Corporation (NasdaqCM:EXAS) for $100 million.

Mdxhealth Sa Announces Resignation of Rudi Mariën as Non-Executive Director

Palmetto GBA’s MolDX Issues Foundational LCD Covering the Indication for SelectMDx for Prostate Cancer

Is MDxHealth (EBR:MDXH) Using Debt In A Risky Way?

Full year 2021 earnings released

Price target increased to €1.20

MDxHealth SA Provides Revenue Guidance for the Full Year 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Here's Why MDxHealth (EBR:MDXH) Can Manage Its Debt Despite Losing Money

First half 2021 earnings released: US$0.12 loss per share (vs US$0.18 loss in 1H 2020)

MDxHealth (EBR:MDXH) Has Debt But No Earnings; Should You Worry?

Full year 2020 earnings released: US$0.34 loss per share (vs US$0.69 loss in FY 2019)

Revenue misses expectations

MDxHealth SA to Report Fiscal Year 2020 Results on Apr 28, 2021

MDxHealth SA to Report Fiscal Year 2020 Results on Mar 03, 2021

MDxHealth SA to Report First Half, 2021 Results on Aug 26, 2021

New 90-day high: €1.07

MDxHealth's (EBR:MDXH) Stock Price Has Reduced 75% In The Past Five Years

New 90-day high: €1.00

Is MDxHealth (EBR:MDXH) Weighed On By Its Debt Load?

Price target raised to €1.00

MDxHealth SA Suspends 2020 Guidance

New 90-day low - €0.69

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera